id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333122-xw8o189s	Blasiak, A.	IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	2020-05-08		.txt	text/plain	5116	351	43	IDentif.AI harnesses a quadratic relationship between therapeutic inputs (e.g. drug and dose) and biological outputs (e.g. quantifiable measurements of efficacy, safety) to experimentally pinpoint optimal combinations from large parameter spaces with a marked reduction in the number of required experiments (Fig. 1 ). The 12drug set included a broad spectrum of repurposed agents that are currently being evaluated in clinical studies for treatment of COVID-19 or being administered in conjunction with these therapies, including remdesivir (RDV), favipiravir (FPV), ritonavir (RTV), lopinavir (LPV), oseltamivir (OSV-P), dexamethasone (DEX), ribavirin (RBV), teicoplanin (TEC), losartan (LST), azithromycin (AZT), chloroquine (CQ), and hydroxychloroquine (HCQ). With a 3-order of magnitude reduction in required tests, we identified a clinically actionable list of 2-,3-, and 4-drug combinations ranked based on viral inhibition efficacy with accompanying safety data against kidney epithelial cells (Vero E6), liver epithelial cells (THLE-2) and cardiomyocytes (AC16). This study harnessed the IDentif.AI platform to interrogate a 12 drug-dose parameter space against the SARS-CoV-2 live virus to develop actionable and optimized combination therapy regimens.	./cache/cord-333122-xw8o189s.txt	./txt/cord-333122-xw8o189s.txt